Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. Among authors: herbst rs. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
Emerging therapies in non-small-cell lung cancer.
Khuri FR, Herbst RS, Fossella FV. Khuri FR, et al. Among authors: herbst rs. Ann Oncol. 2001 Jun;12(6):739-44. doi: 10.1023/a:1011197500223. Ann Oncol. 2001. PMID: 11484947 Free article. Review.
ZD1839 (Iressa) in non-small cell lung cancer.
Herbst RS, Kies MS. Herbst RS, et al. Oncologist. 2002;7 Suppl 4:9-15. doi: 10.1634/theoncologist.7-suppl_4-9. Oncologist. 2002. PMID: 12202783 Free article. Review.
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. LoRusso PM, et al. Among authors: herbst rs. Clin Cancer Res. 2003 Jun;9(6):2040-8. Clin Cancer Res. 2003. PMID: 12796366
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Kris MG, et al. Among authors: herbst rs. JAMA. 2003 Oct 22;290(16):2149-58. doi: 10.1001/jama.290.16.2149. JAMA. 2003. PMID: 14570950 Clinical Trial.
426 results